<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/"><channel><title>心血管出版物</title><link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=202310091 807 33&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U- NVu8003KrCpq8yLQC -<description>心血管亮点：PubMed 的最新结果</description><atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2&amp;ff=20231009180733&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link><docs> http://www.rssboard.org/rss-specification</docs><generator> PubMed RSS 源 (2.17.9.post6+86293ac)</generator><language> zh</language><lastbuilddate> 2023 年 10 月 9 日星期一 22:07:35 +0000</lastbuilddate><pubDate> Mon, 09 Oct 2023 06:00:00 -0400</pubDate><ttl> 120</ttl><item><title>心血管-肾脏-代谢健康：美国心脏协会的总统建议</title><link/>https://pubmed.ncbi.nlm.nih.gov/37807924/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>心血管-肾脏-代谢健康反映了代谢危险因素、慢性肾脏病和心血管系统之间的相互作用，对发病率和死亡率具有深远影响。心血管-肾脏-代谢健康不良会产生多系统后果，其中临床影响最为显着心血管疾病事件和心血管死亡率的高相关发生率。心血管-肾脏-代谢健康状况不佳的患病率很高...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 9 日。doi：10.1161/CIR.0000000000001184。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">心血管-肾脏-代谢健康反映了代谢危险因素、慢性肾脏病和心血管系统之间的相互作用，对发病率和死亡率具有深远影响。心血管-肾脏-代谢健康不良会产生多系统后果，其中临床影响最为显着心血管疾病事件和心血管死亡率的高相关发生率。人群中心血管-肾脏-代谢健康状况不佳的患病率很高，在具有不良健康社会决定因素的人群中，负担不成比例。然而，也存在越来越多的治疗选择对代谢危险因素、肾功能或两者都产生有利影响，同时也具有心脏保护作用。为了改善人群的心血管-肾脏-代谢健康和相关结果，迫切需要（1）更加明确心血管-肾脏-代谢综合征的定义；(2) 一种在整个生命过程中推广的心血管-肾脏-代谢分期方法；(3) 预测算法，包括与心血管-肾脏-代谢健康最相关的暴露和结果，以及(4) 与心血管-肾脏-代谢健康相关的心血管疾病的预防和管理策略，反映了主要专科指南和新兴科学证据之间的协调性。将健康的社会决定因素纳入心血管护理模式中也至关重要-肾脏代谢综合征，并通过促进以患者为中心的跨学科护理方法来减少护理碎片化。该总统咨询提供了有关心血管肾代谢综合征患者护理的定义、分期、预测范式和整体方法的指导以及详细信息有效和公平地增强人口心血管-肾脏-代谢健康的多方面愿景。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37807924/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37807924</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001184>10.1161/CIR.0000000000001184</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37807924</guid><pubDate> Mon, 09 Oct 2023 06:00:00 -0400</pubDate><dc:creator>基亚迪·恩杜梅莱</dc:creator><dc:creator>贾纳尼·兰加斯瓦米</dc:creator><dc:creator>周雪儿</dc:creator><dc:creator>伊恩·J·尼兰</dc:creator><dc:creator>凯瑟琳·R·塔特尔</dc:creator><dc:creator>萨迪亚·汗</dc:creator><dc:creator>约瑟夫·科雷什</dc:creator><dc:creator>罗伊·O·马修</dc:creator><dc:creator>卡丽莎·M·贝克·史密斯</dc:creator><dc:creator>梅赛德斯·R·卡内松</dc:creator><dc:creator>让-皮埃尔·德普雷</dc:creator><dc:creator>詹妮弗·E·何</dc:creator><dc:creator>约书亚·J·约瑟夫</dc:creator><dc:creator>沃尔特·N·克南</dc:creator><dc:creator>阿米特·凯拉</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>卡罗琳·L·莱卡维奇</dc:creator><dc:creator>埃尔德林·刘易斯</dc:creator><dc:creator>凯文·罗</dc:creator><dc:creator>比格·厄兹坎</dc:creator><dc:creator>拉塔·P·帕拉尼阿潘</dc:creator><dc:creator>索纳利·帕特尔</dc:creator><dc:creator>迈克尔·J·彭西纳</dc:creator><dc:creator>蒂芙尼·M·鲍威尔-威利</dc:creator><dc:creator>劳伦斯·斯珀林</dc:creator><dc:creator>萨利姆·维拉尼</dc:creator><dc:creator>杰克逊·T·赖特</dc:creator><dc:creator>拉迪卡·拉吉戈帕尔·辛格</dc:creator><dc:creator>米切尔·SV·埃尔金德</dc:creator><dc:creator>美国心脏协会</dc:creator><dc:date>2023-10-09</dc:date><dc:source>循环</dc:source><dc:title>心血管-肾脏-代谢健康：美国心脏协会的总统建议</dc:title><dc:identifier>下午:37807924</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001184</dc:identifier></item><item><title>心血管肾代谢 (CKM) 综合征的科学和临床管理证据概要：美国心脏协会的科学声明</title><link/>https://pubmed.ncbi.nlm.nih.gov/37807920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>人们越来越认识到肥胖和糖尿病、慢性肾脏病和心血管疾病等代谢危险因素之间的病理生理学相互关系，从而提出了心血管-肾脏-代谢综合征的概念。肾脏代谢综合征与不良心血管和肾脏结局的风险密切相关。此外，还有独特的管理考虑因素...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>流通</b>。2023 年 10 月 9 日。doi：10.1161/CIR.0000000000001186。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">人们越来越认识到肥胖和糖尿病、慢性肾脏病和心血管疾病等代谢危险因素之间的病理生理学相互关系，从而提出了心血管-肾脏-代谢综合征的概念。肾脏代谢综合征与不良心血管和肾脏结局的风险密切相关。此外，对于患有既定心血管疾病和共存代谢危险因素、慢性肾脏疾病或两者兼而有之的个体，还有独特的管理考虑因素。大量文献支持我们的研究对心血管肾代谢综合征个体的预防和管理有科学的认识和方法。然而，在疾病发展机制、临床表型的异质性、心血管肾代谢综合征相关知识方面存在严重差距。健康的社会决定因素和生物风险因素之间的相互作用，以及在竞争风险的背景下准确评估疾病发病率。支持心血管-肾脏-代谢综合征临床护理的数据也存在关键局限性，特别是在早期-生命预防、风险因素筛查、跨学科护理模式、支持生活方式改变和减肥的最佳策略、针对新兴心脏保护和肾脏保护疗法、心血管疾病和慢性肾脏疾病患者的管理以及系统评估的影响除了对科学文献的回顾之外，本科学声明还使用了一系列主要指南，总结了与心血管-肾脏疾病的科学、筛查、预防和管理相关的证据和基本差距。代谢综合征。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37807920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37807920</a> | DOI： <a href=https://doi.org/10.1161/CIR.0000000000001186>10.1161/CIR.0000000000001186</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37807920</guid><pubDate> Mon, 09 Oct 2023 06:00:00 -0400</pubDate><dc:creator>基亚迪·恩杜梅莱</dc:creator><dc:creator>伊恩·J·尼兰</dc:creator><dc:creator>凯瑟琳·R·塔特尔</dc:creator><dc:creator>周雪儿</dc:creator><dc:creator>罗伊·O·马修</dc:creator><dc:creator>萨迪亚·汗</dc:creator><dc:creator>约瑟夫·科雷什</dc:creator><dc:creator>卡丽莎·M·贝克·史密斯</dc:creator><dc:creator>梅赛德斯·R·卡内松</dc:creator><dc:creator>让-皮埃尔·德普雷</dc:creator><dc:creator>詹妮弗·E·何</dc:creator><dc:creator>约书亚·J·约瑟夫</dc:creator><dc:creator>沃尔特·N·克南</dc:creator><dc:creator>阿米特·凯拉</dc:creator><dc:creator>米哈伊尔·N·科西博罗德</dc:creator><dc:creator>卡罗琳·L·莱卡维奇</dc:creator><dc:creator>埃尔德林·刘易斯</dc:creator><dc:creator>凯文·罗</dc:creator><dc:creator>比格·厄兹坎</dc:creator><dc:creator>拉塔·P·帕拉尼阿潘</dc:creator><dc:creator>索纳利·帕特尔</dc:creator><dc:creator>迈克尔·J·彭西纳</dc:creator><dc:creator>蒂芙尼·M·鲍威尔-威利</dc:creator><dc:creator>劳伦斯·斯珀林</dc:creator><dc:creator>萨利姆·维拉尼</dc:creator><dc:creator>杰克逊·T·赖特</dc:creator><dc:creator>拉迪卡·拉吉戈帕尔·辛格</dc:creator><dc:creator>米切尔·SV·埃尔金德</dc:creator><dc:creator>贾纳尼·兰加斯瓦米</dc:creator><dc:creator>美国心脏协会</dc:creator><dc:date>2023-10-09</dc:date><dc:source>循环</dc:source><dc:title>心血管肾代谢 (CKM) 综合征的科学和临床管理证据概要：美国心脏协会的科学声明</dc:title><dc:identifier>下午:37807920</dc:identifier><dc:identifier>号码：10.1161/CIR.0000000000001186</dc:identifier></item><item><title>拮抗性 RALF 肽控制十字花科柱头上的属间杂交屏障</title><link/>https://pubmed.ncbi.nlm.nih.gov/37806310/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>花粉-雌蕊相互作用在植物中建立了种间/属间的合子前杂交障碍。在柱头排斥不需要的花粉对于避免异交至关重要，但可以在导师花粉的支持下克服。这种杂交障碍的机制在很大程度上是未知的。在这里，在拟南芥中，我们证明受体样激酶 FERONIA/CURVY1/ANJEA/HERCULES 受体激酶 1 和细胞壁蛋白 LRX3/4/5 在乳头细胞表面相互作用...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 7 日：S0092-8674(23)00981-9. doi: 10.1016/j.cell.2023.09.003. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">花粉-雌蕊相互作用在植物中建立了种间/属间的合子前杂交障碍。在柱头排斥不需要的花粉对于避免异交至关重要，但可以在导师花粉的支持下克服。这种杂交障碍的机制在很大程度上是未知的。在这里，在拟南芥中，我们证明受体样激酶 FERONIA/CURVY1/ANJEA/HERCULES 受体激酶 1 和细胞壁蛋白 LRX3/4/5 在乳头细胞表面与自分泌斑头 RALF1/22/23/33 肽配体 (sRALF) 相互作用）建立一个锁，阻止不需要的花粉管的渗透。相容的花粉衍生的 RALF10/11/12/13/25/26/30 肽（pRALF）充当关键，击败 sRALF 并实现花粉管渗透。拟南芥柱头与合成的 pRALF，我们解锁了屏障，促进远缘十字花科物种的花粉管穿透，并导致种间/属间杂种胚胎的形成。因此，我们发现了控制种间/属间杂交宽度的“锁和钥匙”系统十字花科的属间杂交。操纵这个系统有望促进作物的广泛杂交。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37806310/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37806310</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.003>10.1016/j.cell.2023.09.003</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37806310</guid><pubDate> Sun, 08 Oct 2023 06:00:00 -0400</pubDate><dc:creator>兰子君</dc:creator><dc:creator>宋子涵</dc:creator><dc:creator>王志娟</dc:creator><dc:creator>李玲</dc:creator><dc:creator>刘逸群</dc:creator><dc:creator>帅花纸</dc:creator><dc:creator>王瑞涵</dc:creator><dc:creator>王继宗</dc:creator><dc:creator>李启云</dc:creator><dc:creator>安德里亚·布莱克曼</dc:creator><dc:creator>张莉</dc:creator><dc:creator>托马斯·德雷塞尔豪斯</dc:creator><dc:creator>董娟</dc:creator><dc:creator>顾洪雅</dc:creator><dc:creator>盛忠</dc:creator><dc:creator>曲丽佳</dc:creator><dc:date>2023-10-08</dc:date><dc:source>细胞</dc:source><dc:title>拮抗性 RALF 肽控制十字花科柱头上的属间杂交屏障</dc:title><dc:identifier>下午:37806310</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.003</dc:identifier></item><item><title>生成重放是海马-前额叶回路中成分推理的基础</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>人类推理依赖于以新的方式重用信息片段。然而，人们对大脑中如何实现组合计算知之甚少。在这里，我们要求参与者解决一系列问题，每个问题都需要从这些问题构建一个整体一组元素。通过功能磁共振成像，我们发现额叶皮层和海马体中新颖构造的物体的表征是相关的和组合的。通过脑磁图，我们发现重放会组装元素...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 30 日：S0092-8674(23)01025-5. doi: 10.1016/j.cell.2023.09.004. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">人类推理依赖于以新的方式重用信息片段。然而，人们对大脑中如何实现组合计算知之甚少。在这里，我们要求参与者解决一系列问题，每个问题都需要从这些问题构建一个整体一组元素。通过功能磁共振成像，我们发现额叶皮层和海马体中新构建的物体的表征是相关的和组合的。通过脑磁图，我们发现重放将元素组装成化合物，每个重放序列都构成了关于可能配置的假设元素的内容随着参与者解决每个谜题而演变，从可预测的元素发展到不确定的元素，并逐渐收敛于正确的配置。总而言之，这些结果表明海马-前额叶电路明显不同的功能与生成重放的作用之间存在计算桥梁在组合推理和假设检验中。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37804832</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.004>10.1016/j.cell.2023.09.004</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804832</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>菲利普·施瓦滕贝克</dc:creator><dc:creator>阿隆巴拉姆</dc:creator><dc:creator>刘云哲</dc:creator><dc:creator>雪莉·马克</dc:creator><dc:creator>蒂莫西·穆勒</dc:creator><dc:creator>雷蒙德·多兰</dc:creator><dc:creator>马修·博特维尼克</dc:creator><dc:creator>泽布·库思-尼尔森</dc:creator><dc:creator>蒂莫西·贝伦斯</dc:creator><dc:date>2023-10-07</dc:date><dc:source>细胞</dc:source><dc:title>生成重放是海马-前额叶回路中成分推理的基础</dc:title><dc:identifier>下午:37804832</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.004</dc:identifier></item><item><title>甲病毒受体 MXRA8 的脊椎动物特异性结合模式</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description> MXRA8 是哺乳动物宿主的基孔肯雅热 (CHIKV) 和其他致关节炎甲病毒的受体。然而，哺乳动物 MXRA8 不会与感染人类且具有禽类宿主的甲病毒结合。在这里，我们表明，禽类（而非哺乳动物）可以充当 MXRA8 的受体。 Sindbis、西部马脑炎 (WEEV) 和相关甲病毒与禽类宿主的受体。鸭 MXRA8 与 WEEV 复合的结构分析揭示了与哺乳动物 MXRA8 结合的反向结合模式。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 10 月 2 日：S0092-8674(23)01029-2。doi：10.1016/j.cell.2023.09.007。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> MXRA8 是哺乳动物宿主的基孔肯雅热 (CHIKV) 和其他致关节炎甲病毒的受体。然而，哺乳动物 MXRA8 不会与感染人类且具有禽类宿主的甲病毒结合。在这里，我们表明，禽类（而非哺乳动物）可以充当 MXRA8 的受体。 Sindbis、西部马脑炎 (WEEV) 和相关甲病毒与禽类宿主的受体。鸭 MXRA8 与 WEEV 复合的结构分析揭示了与哺乳动物 MXRA8 与 CHIKV 结合相比的反向结合模式。只有禽类 MXRA8 的结构域 1 与 WEEV E1 结合，并且与 WEEV E2 没有明显的接触。利用这些结果，我们生成了一种嵌合禽类-哺乳动物 MXRA8 诱饵受体，它可以在体外和体内中和来自不同抗原组的多种甲病毒的感染。因此，不同的甲病毒可以结合由 WEEV E2 编码的 MXRA8不同的脊椎动物类别具有不同的参与模式，这使得能够开发广谱抑制剂。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37804831</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.007>10.1016/j.cell.2023.09.007</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804831</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>奥弗·齐默尔曼</dc:creator><dc:creator>麦克斯韦·齐默尔曼</dc:creator><dc:creator>沙拉瓦南拉朱</dc:creator><dc:creator>克里斯托弗·纳尔逊</dc:creator><dc:creator>约翰·埃里科</dc:creator><dc:creator>艾米丽·马登</dc:creator><dc:creator>奥特姆·C·福尔摩斯</dc:creator><dc:creator>艾哈迈德·奥·哈桑</dc:creator><dc:creator>劳拉·范布拉根</dc:creator><dc:creator>阿瑟·S·金</dc:creator><dc:creator>卢卡斯·J·亚当斯</dc:creator><dc:creator>凯瑟琳·巴索尔</dc:creator><dc:creator>布拉德利·M·怀特纳</dc:creator><dc:creator>萨斯维克·帕拉库蒂</dc:creator><dc:creator>汉娜·G·戴维斯-亚当斯</dc:creator><dc:creator>孙成群</dc:creator><dc:creator>塞隆·吉利兰</dc:creator><dc:creator>詹姆斯·T·欧尼斯特</dc:creator><dc:creator>马洪明</dc:creator><dc:creator>格雷戈里·D·埃贝尔</dc:creator><dc:creator>克里斯蒂安·兹马塞克</dc:creator><dc:creator>理查德·H·苏伊尔曼</dc:creator><dc:creator>威廉·B·克里姆斯特拉</dc:creator><dc:creator>戴德·H·弗里蒙特</dc:creator><dc:creator>迈克尔·戴蒙德</dc:creator><dc:date>2023-10-07</dc:date><dc:source>细胞</dc:source><dc:title>甲病毒受体 MXRA8 的脊椎动物特异性结合模式</dc:title><dc:identifier>下午:37804831</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.007</dc:identifier></item><item><title>精氨酸通过 RBM39 重新编程肝癌的代谢</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>代谢重编程是癌症的一个标志。然而，代谢重编程的机制以及代谢改变如何反过来增强致瘤性却知之甚少。在此，我们报告称，尽管精氨酸表达降低，但小鼠和患者肝细胞癌 (HCC) 中的精氨酸水平升高合成基因。由于摄取增加和精氨酸到多胺转化的减少，肿瘤细胞积累了高水平的精氨酸。重要的是，高水平的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Cell</b> . 2023 年 9 月 26 日：S0092-8674(23)01032-2. doi: 10.1016/j.cell.2023.09.011. 印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">代谢重编程是癌症的一个标志。然而，代谢重编程的机制以及代谢改变如何反过来增强致瘤性却知之甚少。在此，我们报告称，尽管精氨酸表达降低，但小鼠和患者肝细胞癌 (HCC) 中的精氨酸水平升高合成基因。由于摄取增加和精氨酸到多胺转化的减少，肿瘤细胞积累高水平的精氨酸。重要的是，高水平的精氨酸通过进一步的代谢重编程（包括葡萄糖、氨基酸、核苷酸和脂肪的变化）促进肿瘤形成从机制上讲，精氨酸结合 RNA 结合基序蛋白 39 (RBM39) 来控制代谢基因的表达。RBM39 介导的天冬酰胺合成上调导致精氨酸摄取增强，形成正反馈循环以维持高精氨酸水平和致癌代谢。因此，精氨酸是一种第二信使分子，可以重新编程新陈代谢以促进肿瘤生长。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37804830</a> | DOI： <a href=https://doi.org/10.1016/j.cell.2023.09.011>10.1016/j.cell.2023.09.011</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804830</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>德克·莫斯曼</dc:creator><dc:creator>克里斯托夫·穆勒</dc:creator><dc:creator>素锦公园</dc:creator><dc:creator>布伦丹·瑞贝克</dc:creator><dc:creator>马可·哥伦比</dc:creator><dc:creator>娜塔莉·里特</dc:creator><dc:creator>戴安娜·魏森伯格</dc:creator><dc:creator>伊娃·达泽特</dc:creator><dc:creator>迈雷内·科托·莱雷纳</dc:creator><dc:creator>桑德罗·努西福罗</dc:creator><dc:creator>劳里安·布卢卡茨</dc:creator><dc:creator>坎纳尔·埃坎</dc:creator><dc:creator>维罗尼卡·希门尼斯</dc:creator><dc:creator>萨尔瓦多·皮斯库利奥</dc:creator><dc:creator>法蒂玛·博斯</dc:creator><dc:creator>路易吉·M·泰拉恰诺</dc:creator><dc:creator>乌韦·绍尔</dc:creator><dc:creator>马库斯·H·海姆</dc:creator><dc:creator>迈克尔·霍尔</dc:creator><dc:date>2023-10-07</dc:date><dc:source>细胞</dc:source><dc:title>精氨酸通过 RBM39 重新编程肝癌的代谢</dc:title><dc:identifier>下午:37804830</dc:identifier><dc:identifier> doi:10.1016/j.cell.2023.09.011</dc:identifier></item><item><title>三尖瓣学术研究联盟对三尖瓣反流的定义和试验终点</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>随着多项自然史研究显示，即使在调整了多种合并症之后，三尖瓣反流 (TR) 患者的病理生理学、病因、治疗和结果的兴趣也随之增长，这些研究表明，随着 TR 严重程度的增加，结果也会逐渐恶化。瓣膜手术与高院内死亡率相关，导致经导管治疗方案的发展。第一个三尖瓣手术的目的... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> J Am Coll Cardiol。2023 年 9 月 28 日：S0735-1097(23)06403-3。doi：10.1016/j.jacc.2023.08.008。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">随着多项自然史研究显示，即使在调整了多种合并症之后，三尖瓣反流 (TR) 患者的病理生理学、病因、治疗和结果的兴趣也随之增长，这些研究表明，随着 TR 严重程度的增加，结果也会逐渐恶化。瓣膜手术与高院内死亡率相关，导致经导管治疗方案的发展。第一份三尖瓣学术研究联盟文件的目的是标准化疾病病因和严重程度的定义，以及以下试验的终点：旨在解决我们在 TR 患者识别和管理方面的知识差距。标准化试验终点应提供一致性，并能够在临床试验之间进行有意义的比较。第二份三尖瓣学术研究联盟文件将重点关注进一步定义试验终点，并将讨论试验设计选项。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37804294</a> | DOI： <a href=https://doi.org/10.1016/j.jacc.2023.08.008>10.1016/j.jacc.2023.08.008</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804294</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>丽贝卡·T·哈恩</dc:creator><dc:creator>马修·K·劳勒</dc:creator><dc:creator>查尔斯·J·戴维森</dc:creator><dc:creator>维奈·巴德瓦尔</dc:creator><dc:creator>安娜桑尼诺</dc:creator><dc:creator>欧内斯特·斯皮策</dc:creator><dc:creator>菲利普·鲁兹</dc:creator><dc:creator>布莱恩·R·林德曼</dc:creator><dc:creator>严·托皮尔斯基</dc:creator><dc:creator>苏珊娜·J·巴伦</dc:creator><dc:creator>斯科特·查德登</dc:creator><dc:creator>奥马尔·K·哈利克</dc:creator><dc:creator>吉尔伯特·HL·唐</dc:creator><dc:creator>毛里齐奥·塔拉马索</dc:creator><dc:creator>保罗·格雷伯恩</dc:creator><dc:creator>路易吉·巴达诺</dc:creator><dc:creator>乔纳森·莱普西克</dc:creator><dc:creator>乔安·林登菲尔德</dc:creator><dc:creator>史蒂芬·温德克</dc:creator><dc:creator>斯里坎特·韦穆拉帕利</dc:creator><dc:creator>比约恩·雷德福斯</dc:creator><dc:creator>玛丽亚·C·阿鲁</dc:creator><dc:creator>大卫·J·科恩</dc:creator><dc:creator>何塞普·罗德斯·卡包</dc:creator><dc:creator>戈拉夫·艾拉瓦迪</dc:creator><dc:creator>迈克尔·麦克</dc:creator><dc:creator>奥里·本-耶胡达</dc:creator><dc:creator>马丁·B·莱昂</dc:creator><dc:creator>约尔格·豪斯莱特</dc:creator><dc:creator>TVARC指导委员会</dc:creator><dc:date>2023-10-07</dc:date><dc:source>美国心脏病学会杂志</dc:source><dc:title>三尖瓣学术研究联盟对三尖瓣反流的定义和试验终点</dc:title><dc:identifier>下午:37804294</dc:identifier><dc:identifier> doi:10.1016/j.jacc.2023.08.008</dc:identifier></item><item><title> Mavacamten：用于治疗梗阻性肥厚性心肌病的一流肌球蛋白抑制剂</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804245/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description> Mavacamten 是美国食品和药物管理局批准的一流、靶向、心脏特异性肌球蛋白抑制剂，用于治疗患有纽约心脏协会 II 级和 III 级梗阻性肥厚性心肌病 (oHCM) 的成人患者。针对过度收缩表型，该表型在疾病的病理生理学中起着至关重要的作用。在 2 期和 3 期临床试验中，mavacamten 耐受性良好，左心室流出量减少...... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 7 日：ehad637。doi：10.1093/eurheartj/ehad637。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> Mavacamten 是美国食品和药物管理局批准的一流、靶向、心脏特异性肌球蛋白抑制剂，用于治疗患有纽约心脏协会 II 级和 III 级梗阻性肥厚性心肌病 (oHCM) 的成人患者。针对过度收缩表型，该表型在疾病的病理生理学中起着至关重要的作用。在 2 期和 3 期临床试验中，mavacamten 耐受性良好，可降低左心室流出道梯度，改善运动能力和症状，并与改善相关其他临床相关参数，例如患者报告的结果和循环生物标志物。此外，mavacamten 治疗与多模态成像研究中有利的心脏重塑证据相关。Mavacamten 大大降低了 oHCM 和室间隔复位治疗候选者的指南资格。药物难治性症状。在本文中，回顾了 mavacamten 在有症状 oHCM 患者中已完成和正在进行的临床研究的可用疗效和安全性数据。长期扩展研究可能有助于解决与 mavacamten 在当前 oHCM 管理算法中定位相关的问题、与背景治疗的相互作用，以及除了缓解左心室流出道梗阻症状之外改善疾病的潜力。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804245/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37804245</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad637>10.1093/eurheartj/ehad637</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804245</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>尤金·布劳瓦尔德</dc:creator><dc:creator>萨拉·萨贝里</dc:creator><dc:creator>西奥多·P·亚伯拉罕</dc:creator><dc:creator>佩里·埃利奥特</dc:creator><dc:creator>亚科波·奥利沃托</dc:creator><dc:date>2023-10-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>Mavacamten：用于治疗梗阻性肥厚性心肌病的一流肌球蛋白抑制剂</dc:title><dc:identifier>下午:37804245</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad637</dc:identifier></item><item><title>围产期心肌病的 20 年人群研究</title><link/>https://pubmed.ncbi.nlm.nih.gov/37804234/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>结论：PPCM 在怀孕期间影响了 4950 名妇女中的 1 名。这种情况与母亲和儿童的相当大的发病率和死亡率有关。调查高危妇女的门槛应该较低。长期随访，尽管明显恢复，应该考虑。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 7 日：ehad626。doi：10.1093/eurheartj/ehad626。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景和目的：人们对欧洲围产期心肌病 (PPCM) 的流行病学知之甚少，也缺乏长期结果的数据。对 1998 年至 2017 年苏格兰经验证的 PPCM 病例进行了一项回顾性、观察性、人群水平的研究。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：纳入在怀孕期间因推测新发左心室收缩功能障碍而住院且没有明确其他原因的女性。每个病例与 10 名对照者相匹配。确定发病率和危险因素。检查母亲和儿童的发病率和死亡率。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：PPCM 的发生率为 4950 例分娩中 1 例。在 225 名患有 PPCM 的女性中，发现肥胖、妊娠高血压疾病和多胎妊娠与患有该疾病有关。中位时间超过 8.3 年（超声心动图结果为 9.7 年） ），8% 的 PPCM 女性死亡，75% 的女性因任何原因至少再住院一次。PPCM 女性的死亡率和再住院率分别是对照组的约 12 倍和约 3 倍。全因的综合数据死亡、机械循环支持或心脏移植的比例为 14%。左心室恢复的比例为 76%，在康复者中，尽管初步恢复，但仍有 13% 的左心室收缩功能继续下降。患有 PPCM 的女性所生孩子的数量是对照组的 5 倍，并且在中位数 8.8 年内，她们的心血管疾病发病率高出 3 倍。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论：PPCM 在怀孕期间影响了 4950 名妇女中的 1 名。这种情况与母亲和儿童的相当大的发病率和死亡率有关。调查高危妇女的门槛应该较低。长期随访，尽管明显恢复，应该考虑。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37804234/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37804234</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad626>10.1093/eurheartj/ehad626</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37804234</guid><pubDate> Sat, 07 Oct 2023 06:00:00 -0400</pubDate><dc:creator>艾丽丝·M·杰克逊</dc:creator><dc:creator>马克·麦戛尔尼</dc:creator><dc:creator>卡特里奥娜·布鲁克斯班克</dc:creator><dc:creator>卡罗琳·布朗</dc:creator><dc:creator>达纳·道森</dc:creator><dc:creator>马克·弗朗西斯</dc:creator><dc:creator>艾伦·贾普</dc:creator><dc:creator>维拉·伦尼</dc:creator><dc:creator>史蒂芬·J·莱斯利</dc:creator><dc:creator>托马斯·马丁</dc:creator><dc:creator>保罗·尼尔里</dc:creator><dc:creator>索米亚·文卡塔苏布拉曼尼安</dc:creator><dc:creator>黛布拉·维克斯</dc:creator><dc:creator>罗宾·威尔</dc:creator><dc:creator>约翰·JV·麦克默里</dc:creator><dc:creator>帕迪普·S·琼德</dc:creator><dc:creator>马克·皮特里</dc:creator><dc:date>2023-10-07</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>围产期心肌病的 20 年人群研究</dc:title><dc:identifier>下午:37804234</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad626</dc:identifier></item><item><title>资源有限，指南有限？致力于跨环境提供适当的、因地制宜的心血管护理</title><link/>https://pubmed.ncbi.nlm.nih.gov/37801634/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>无摘要</description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 年 10 月 6 日：ehad253。doi：10.1093/eurheartj/ehad253。印刷前在线。</p><p><b>无摘要</b></p><p style="color: lightgray">PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37801634/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37801634</a> | DOI： <a href=https://doi.org/10.1093/eurheartj/ehad253>10.1093/eurheartj/ehad253</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37801634</guid><pubDate> Fri, 06 Oct 2023 06:00:00 -0400</pubDate><dc:creator>多米尼克·维沃特</dc:creator><dc:date>2023-10-06</dc:date><dc:source>欧洲心脏杂志</dc:source><dc:title>资源有限，指南有限？致力于跨环境提供适当的、因地制宜的心血管护理</dc:title><dc:identifier>下午：37801634</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad253</dc:identifier></item><item><title>近期发作的扩张型心肌病的心肌恢复：&lt;em>;CDCP1&lt;/em>; 与心脏纤维化的作用</title><link/>https://pubmed.ncbi.nlm.nih.gov/37800334/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>结论：CDCP1 可能在新发 DCM 的心肌恢复中发挥重要作用，并主要通过减轻心脏纤维化来介导其作用。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 10 月 6 日。doi：10.1161/CIRCRESAHA.123.323200。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：扩张型心肌病（DCM）是心力衰竭的主要原因，死亡率很高。DCM相关心力衰竭患者的心肌恢复情况差异很大，一些患者对标准药物治疗反应很少或没有反应。广泛的关联研究可以不可知地识别生物标志物，并为 DCM 心肌恢复的生物学提供新的见解。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">方法：对 686 名接受标准药物治疗的新发 DCM 白人受试者进行了一项针对左心室射血分数变化的全基因组关联研究。随后对全基因组关联研究信号进行了功能验证，并在相关细胞模型中进行了研究，以了解分子机制。可能导致左心室射血分数变化的机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结果：全基因组关联研究确定了一个高度提示性的位点，该位点映射到<i>CDCP1</i> （含有蛋白1的CUB结构域）基因（rs6773435； <i>P</i> =7.12×10 <sup>-</sup> <sup>7</sup> ）的5&#39;侧翼区域。心脏功能得到改善， <i>CDCP1</i>转录减少。CDCP1 表达在人心脏成纤维细胞 (HCF) 中显着上调，以响应 PDGF（血小板源性生长因子）信号传导，敲低 CDCP1 显着抑制 HCF 增殖并降低 AKT 磷酸化。 HCF 中 CDCP1 敲除后的结果支持了 CDCP1 调节 HCF 增殖和有丝分裂的结论。此外，HCF 中 CDCP1 敲除导致可溶性 ST2 的表达显着降低，ST2 是心力衰竭和心脏纤维化诱导物的预后生物标志物。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">结论： <i>CDCP1</i>可能在新发 DCM 的心肌恢复中发挥重要作用，并主要通过减轻心脏纤维化来介导其作用。</p><p style="color: lightgray"> PMID： <a href="https://pubmed.ncbi.nlm.nih.gov/37800334/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37800334</a> | DOI： <a href=https://doi.org/10.1161/CIRCRESAHA.123.323200>10.1161/CIRCRESAHA.123.323200</a></p></div> ]]>;</content:encoded><guid ispermalink="false">发布：37800334</guid><pubDate> Fri, 06 Oct 2023 06:00:00 -0400</pubDate><dc:creator>刘端</dc:creator><dc:creator>王敏</dc:creator><dc:creator>维沙坎塔·穆尔蒂</dc:creator><dc:creator>丹尼斯·M·麦克纳马拉</dc:creator><dc:creator>阮青青</dc:creator><dc:creator>特鲁迪·J·飞利浦</dc:creator><dc:creator>赫里扬舒·维亚斯</dc:creator><dc:creator>高焕耀</dc:creator><dc:creator>乔丹·萨尼</dc:creator><dc:creator>兰德尔·C·斯塔林</dc:creator><dc:creator>莱斯利·T·库珀</dc:creator><dc:creator>米歇尔·K·斯基姆</dc:creator><dc:creator>安东尼·巴茨勒</dc:creator><dc:creator>格雷戈里·D·詹金斯</dc:creator><dc:creator>西蒙娜·巴雷拉</dc:creator><dc:creator>西尔瓦娜·佩莱吉</dc:creator><dc:creator>路易莎·梅斯特罗尼</dc:creator><dc:creator>马可·梅洛</dc:creator><dc:creator>吉安弗兰科·西纳格拉</dc:creator><dc:creator>弗洛伦斯·皮内</dc:creator><dc:creator>简·克雷吉</dc:creator><dc:creator>安娜·查卢普卡</dc:creator><dc:creator>乔丹·D·米勒</dc:creator><dc:creator>帕斯卡·德·格鲁特</dc:creator><dc:creator>丹尼尔·J·楚姆珀林</dc:creator><dc:creator>理查德·M·温希尔博姆</dc:creator><dc:creator>纳文·L·佩雷拉</dc:creator><dc:creator>IMAC-2 调查员</dc:creator><dc:date>2023-10-06</dc:date><dc:source>流通研究</dc:source><dc:title>近期发作的扩张型心肌病的心肌恢复：&lt;em>;CDCP1&lt;/em>; 与心脏纤维化的作用</dc:title><dc:identifier>下午:37800334</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323200</dc:identifier></item><item><title>胱硫醚 γ-裂解酶与 p53 的结合中断促进内皮衰老</title><link/>https://pubmed.ncbi.nlm.nih.gov/37800327/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff =20231009180733&amp;v=2.17.9.post6+86293ac<description>结论：与衰老相关的血管修复损伤部分是由血管保护酶 CSE 决定的。 </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Circ Res. 2023 年 10 月 6 日。doi：10.1161/CIRCRESAHA.123.323084。印刷前在线。</p><p><b>抽象的</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">背景：高龄与心血管疾病的发展明确相关；然而，导致内皮细胞再生减少的机制仍知之甚少。在这里，我们研究了内皮细胞衰老中影响内皮细胞转录和损伤后血管修复的新机制。 </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Native endothelial cells were isolated from young (20±3.4 years) and aged (80±2.3 years) individuals and subjected to molecular analyses to assess global transcriptional and metabolic changes. in vitro studies were conducted using primary human and murine endothelial cells. A murine aortic reendothelialization model was used to examine endothelial cell regenerative capacity in vivo. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: RNA sequencing of native endothelial cells revealed that aging resulted in p53-mediated reprogramming to express senescence-associated genes and suppress glycolysis. Reduced glucose uptake and ATP contributed to attenuated assembly of the telomerase complex, which was required for endothelial cell proliferation. Enhanced p53 activity in aging was linked to its acetylation on K120 due to enhanced activity of the acetyltransferase MOZ (monocytic leukemic zinc finger). Mechanistically, p53 acetylation and translocation were, at least partially, attributed to the loss of the vasoprotective enzyme, CSE (cystathionine γ-lyase). CSE physically anchored p53 in the cytosol to prevent its nuclear translocation and in its absence inhibited Akt-mediated MOZ phosphorylation, which in turn increased MOZ activity and subsequently p53 acetylation. In mice, the endothelial cell-specific deletion of CSE activated p53, induced premature endothelial senescence, and arrested vascular repair after injury. In contrast, the adeno-associated virus 9-mediated reexpression of an active CSE mutant retained p53 in the cytosol, maintained endothelial glucose metabolism and proliferation, and prevented endothelial cell senescence. Adenoviral overexpression of CSE in native endothelial cells from aged individuals maintained low p53 activity and reactivated telomerase to revert endothelial cell senescence. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: Aging-associated impairment of vascular repair is partly determined by the vasoprotective enzyme CSE.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37800327/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37800327</a> | DOI: <a href=https://doi.org/10.1161/CIRCRESAHA.123.323084>10.1161/CIRCRESAHA.123.323084</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37800327</guid><pubDate> Fri, 06 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Jiong Hu</dc:creator><dc:creator> Matthias S Leisegang</dc:creator><dc:creator> Mario Looso</dc:creator><dc:creator> Maria-Kyriaki Drekolia</dc:creator><dc:creator> Janina Wittig</dc:creator><dc:creator> Janina Mettner</dc:creator><dc:creator> Christina Karantanou</dc:creator><dc:creator> Anastasia Kyselova</dc:creator><dc:creator> Gabrjela Dumbovic</dc:creator><dc:creator> Xiaoming Li</dc:creator><dc:creator> Yuanyuan Li</dc:creator><dc:creator> Stefan Guenther</dc:creator><dc:creator> David John</dc:creator><dc:creator> Mauro Siragusa</dc:creator><dc:creator> Sven Zukunft</dc:creator><dc:creator> James Oo</dc:creator><dc:creator> Ilka Wittig</dc:creator><dc:creator> Susanne Hille</dc:creator><dc:creator> Andreas Weigert</dc:creator><dc:creator> Stefan Knapp</dc:creator><dc:creator> Ralf P Brandes</dc:creator><dc:creator> Oliver J Müller</dc:creator><dc:creator> Andreas Papapetropoulos</dc:creator><dc:creator> Fragiska Sigala</dc:creator><dc:creator> Gergana Dobreva</dc:creator><dc:creator> Baktybek Kojonazarov</dc:creator><dc:creator> Ingrid Fleming</dc:creator><dc:creator> Sofia-Iris Bibli</dc:creator><dc:date> 2023-10-06</dc:date><dc:source> Circulation research</dc:source><dc:title> Disrupted Binding of Cystathionine γ-Lyase to p53 Promotes Endothelial Senescence</dc:title><dc:identifier> pmid:37800327</dc:identifier><dc:identifier> doi:10.1161/CIRCRESAHA.123.323084</dc:identifier></item><item><title> Brain endothelium: a nexus for cerebral small vessel disease</title><link/> https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Aug 29:ehad526. doi: 10.1093/eurheartj/ehad526. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37798089/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37798089</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad526>10.1093/eurheartj/ehad526</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37798089</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Martin Dichgans</dc:creator><dc:creator> Frank M Faraci</dc:creator><dc:creator> BRENDA Network</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Brain endothelium: a nexus for cerebral small vessel disease</dc:title><dc:identifier> pmid:37798089</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad526</dc:identifier></item><item><title> The European Society of Cardiology working group on cardiovascular pharmacotherapy</title><link/> https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 4:ehad651. doi: 10.1093/eurheartj/ehad651. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37796825/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37796825</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad651>10.1093/eurheartj/ehad651</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37796825</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Juan Carlos Kaski</dc:creator><dc:creator> Alexander Niessner</dc:creator><dc:creator> Dobromir Dobrev</dc:creator><dc:creator> Bianca Rocca</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> The European Society of Cardiology working group on cardiovascular pharmacotherapy</dc:title><dc:identifier> pmid:37796825</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad651</dc:identifier></item><item><title> Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines</title><link/> https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad581. doi: 10.1093/eurheartj/ehad581. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND AND AIMS: Identifying patients with hypertrophic cardiomyopathy (HCM) who are candidates for implantable cardioverter defibrillator (ICD) implantation in primary prevention for sudden cardiac death (SCD) is crucial. The aim of this study was to externally validate the 2022 European Society of Cardiology (ESC) model and other guideline-based ICD class of recommendation (ICD-COR) models and explore the utility of late gadolinium enhancement (LGE) in further risk stratification. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Seven hundred and seventy-four consecutive patients who underwent cardiac magnetic resonance imaging were retrospectively enrolled. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Forty-six (5.9%) patients reached the SCD-related endpoint during 7.4 ± 2.5 years of follow-up. Patients suffering from SCD had higher ESC Risk-SCD score (4.3 ± 2.4% vs. 2.8 ± 2.1%, P &lt; .001) and LGE extent (13.7 ± 9.4% vs. 4.9 ± 6.6%, P &lt; .001). Compared with the 2014 ESC model, the 2022 ESC model showed increased area under the curve (.76 vs. .63), sensitivity (76.1% vs. 43.5%), positive predictive value (16.8% vs. 13.6%), and negative predictive value (98.1% vs. 95.9%). The C-statistics for SCD prediction of 2011 American College of Cardiology (ACC)/American Heart Association (AHA), 2014 ESC, 2020 AHA/ACC, and 2022 ESC models were .68, .64, .76 and .78, respectively. Furthermore, in patients without extensive LGE, LGE ≥5% was responsible for seven-fold SCD risk after multivariable adjustment. Whether in ICD-COR II or ICD-COR III, patients with LGE ≥5% and &lt;15% showed significantly worse prognosis than those with LGE &lt;5% (all P &lt; .001). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: The 2022 ESC model performed better than the 2014 ESC model with especially improved sensitivity. LGE enabled further risk stratification based on current guidelines.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37795986/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37795986</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad581>10.1093/eurheartj/ehad581</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37795986</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Jiaxin Wang</dc:creator><dc:creator> Shujuan Yang</dc:creator><dc:creator> Xuan Ma</dc:creator><dc:creator> Kankan Zhao</dc:creator><dc:creator> Kai Yang</dc:creator><dc:creator> Shiqin Yu</dc:creator><dc:creator> Gang Yin</dc:creator><dc:creator> Zhixiang Dong</dc:creator><dc:creator> Yanyan Song</dc:creator><dc:creator> Chen Cui</dc:creator><dc:creator> Jinghui Li</dc:creator><dc:creator> Chuangshi Wang</dc:creator><dc:creator> Jun Hao</dc:creator><dc:creator> Minjie Lu</dc:creator><dc:creator> Xiuyu Chen</dc:creator><dc:creator> Shihua Zhao</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Assessment of late gadolinium enhancement in hypertrophic cardiomyopathy improves risk stratification based on current guidelines</dc:title><dc:identifier> pmid:37795986</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad581</dc:identifier></item><item><title> Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association</title><link/> https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic prophylaxis administered in the setting of invasive procedures in the prevention of infective endocarditis in high-risk patients. Moreover, previous observational studies that examined the association of nondental invasive procedures with the... </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 5. doi: 10.1161/CIR.0000000000001180. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> There have been no published prospective randomized clinical trials that have: (1) established an association between invasive dental and nondental invasive procedures and risk of infective endocarditis; or (2) defined the efficacy and safety of antibiotic prophylaxis administered in the setting of invasive procedures in the prevention of infective endocarditis in high-risk patients. Moreover, previous observational studies that examined the association of nondental invasive procedures with the risk of infective endocarditis have been limited by inadequate sample size. They have typically focused on a few potential at-risk surgical and nonsurgical invasive procedures. However, recent investigations from Sweden and England that used nationwide databases and demonstrated an association between nondental invasive procedures, and the subsequent development of infective endocarditis (in particular, in high-risk patients with infective endocarditis) prompted the development of the current science advisory.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37795631/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37795631</a> | DOI: <a href=https://doi.org/10.1161/CIR.0000000000001180>10.1161/CIR.0000000000001180</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37795631</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Larry M Baddour</dc:creator><dc:creator> Imre Janszky</dc:creator><dc:creator> Martin H Thornhill</dc:creator><dc:creator> Zerelda Esquer Garrigos</dc:creator><dc:creator> Daniel C DeSimone</dc:creator><dc:creator> Karen Welty-Wolf</dc:creator><dc:creator> Annette L Baker</dc:creator><dc:creator> Pei-Ni Jone</dc:creator><dc:creator> Bernard Prendergast</dc:creator><dc:creator> Mark J Dayer</dc:creator><dc:creator> American Heart Association Council on Lifelong Congenital Heart Disease and Heart Health in the Young (Young Hearts) and Council on Cardiovascular and Stroke Nursing</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> Circulation</dc:source><dc:title> Nondental Invasive Procedures and Risk of Infective Endocarditis: Time for a Revisit: A Science Advisory From the American Heart Association</dc:title><dc:identifier> pmid:37795631</dc:identifier><dc:identifier> doi:10.1161/CIR.0000000000001180</dc:identifier></item><item><title> Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVRIII Study</title><link/> https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: By 12 years after the Norwood operation, shunt type has minimal association with RVEF, peak Vo(2), complication rates, and transplant-free survival. RVEF is preserved among the subgroup of survivors who underwent CMR assessment. Low transplant-free survival, poor exercise performance, and accruing morbidities highlight the need for innovative strategies to improve long-term outcomes in patients with hypoplastic left heart syndrome. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 5. doi: 10.1161/CIRCULATIONAHA.123.065192. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> OBJECTIVE: In the SVR trial (Single Ventricle Reconstruction), newborns with hypoplastic left heart syndrome were randomly assigned to receive a modified Blalock-Taussig-Thomas shunt (mBTTS) or a right ventricle-to-pulmonary artery shunt (RVPAS) at Norwood operation. Transplant-free survival was superior in the RVPAS group at 1 year, but no longer differed by treatment group at 6 years; both treatment groups had accumulated important morbidities. In the third follow-up of this cohort (SVRIII [Long-Term Outcomes of Children With Hypoplastic Left Heart Syndrome and the Impact of Norwood Shunt Type]), we measured longitudinal outcomes and their risk factors through 12 years of age. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Annual medical history was collected through record review and telephone interviews. Cardiac magnetic resonance imaging (CMR), echocardiogram, and cycle ergometry cardiopulmonary exercise tests were performed at 10 through 14 years of age among participants with Fontan physiology. Differences in transplant-free survival and complication rates (eg, arrhythmias or protein-losing enteropathy) were identified through 12 years of age. The primary study outcome was right ventricular ejection fraction (RVEF) by CMR, and primary analyses were according to shunt type received. Multivariable linear and Cox regression models were created for RVEF by CMR and post-Fontan transplant-free survival. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Among 549 participants enrolled in SVR, 237 of 313 (76%; 60.7% male) transplant-free survivors (mBTTS, 105 of 147; RVPAS, 129 of 161; both, 3 of 5) participated in SVRIII. RVEF by CMR was similar in the shunt groups (RVPAS, 51±9.6 [n=90], and mBTTS, 52±7.4 [n=75]; <i>P</i> =0.43). The RVPAS and mBTTS groups did not differ in transplant-free survival by 12 years of age (163 of 277 [59%] versus 144 of 267 [54%], respectively; <i>P</i> =0.11), percentage predicted peak Vo <sub>2</sub> for age and sex (74±18% [n=91] versus 72±18% [n=84]; <i>P</i> =0.71), or percentage predicted work rate for size and sex (65±20% versus 64±19%; <i>P</i> =0.65). The RVPAS versus mBTTS group had a higher cumulative incidence of protein-losing enteropathy (5% versus 2%; <i>P</i> =0.04) and of catheter interventions (14 versus 10 per 100 patient-years; <i>P</i> =0.01), but had similar rates of other complications. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: By 12 years after the Norwood operation, shunt type has minimal association with RVEF, peak Vo <sub>2</sub> , complication rates, and transplant-free survival. RVEF is preserved among the subgroup of survivors who underwent CMR assessment. Low transplant-free survival, poor exercise performance, and accruing morbidities highlight the need for innovative strategies to improve long-term outcomes in patients with hypoplastic left heart syndrome. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT00115934.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37795623/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37795623</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065192>10.1161/CIRCULATIONAHA.123.065192</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37795623</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Caren S Goldberg</dc:creator><dc:creator> Felicia Trachtenberg</dc:creator><dc:creator> J William Gaynor</dc:creator><dc:creator> William T Mahle</dc:creator><dc:creator> Chitra Ravishankar</dc:creator><dc:creator> Steven M Schwartz</dc:creator><dc:creator> James F Cnota</dc:creator><dc:creator> Richard G Ohye</dc:creator><dc:creator> Russell Gongwer</dc:creator><dc:creator> Michael Taylor</dc:creator><dc:creator> Stephen Paridon</dc:creator><dc:creator> Peter C Frommelt</dc:creator><dc:creator> Katherine Afton</dc:creator><dc:creator> Andrew M Atz</dc:creator><dc:creator> Kristin M Burns</dc:creator><dc:creator> Jon A Detterich</dc:creator><dc:creator> Kevin D Hill</dc:creator><dc:creator> Antonio G Cabrera</dc:creator><dc:creator> Alan B Lewis</dc:creator><dc:creator> Christian Pizarro</dc:creator><dc:creator> Amee Shah</dc:creator><dc:creator> Binu Sharma</dc:creator><dc:creator> Jane W Newburger</dc:creator><dc:creator> Pediatric Heart Network Investigators</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> Circulation</dc:source><dc:title> Longitudinal Follow-Up of Children With HLHS and Association Between Norwood Shunt Type and Long-Term Outcomes: The SVRIII Study</dc:title><dc:identifier> pmid:37795623</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.065192</dc:identifier></item><item><title> Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</title><link/> https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved. </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> <b>Circulation</b> . 2023 Oct 5. doi: 10.1161/CIRCULATIONAHA.123.064751. Online ahead of print.</p><p> <b>ABSTRACT</b> </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> BACKGROUND: We investigated the usefulness of invasive coronary function testing to diagnose the cause of angina in patients with no obstructive coronary arteries. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> METHODS: Outpatients referred for coronary computed tomography angiography in 3 hospitals in the United Kingdom were prospectively screened. After coronary computed tomography angiography, patients with unobstructed coronary arteries, and who consented, underwent invasive endotyping. The diagnostic assessments included coronary angiography, fractional flow reserve (patient excluded if ≤0.80), and, for those without obstructive coronary artery disease, coronary flow reserve (abnormal &lt;2.0), index of microvascular resistance (abnormal ≥25), and intracoronary infusion of acetylcholine (0.182, 1.82, and 18.2 μg/mL; 2 mL/min for 2 minutes) to assess for microvascular and coronary spasm. Participants were randomly assigned to disclosure of the results of the coronary function tests to the invasive cardiologist (intervention group) or nondisclosure (control group, blinded). In the control group, a diagnosis of vasomotor angina was based on medical history, noninvasive tests, and coronary angiography. The primary outcome was the between-group difference in the reclassification rate of the initial diagnosis on the basis of coronary computed tomography angiography versus the final diagnosis after invasive endotyping. The Seattle Angina Questionnaire summary score and Treatment Satisfaction Questionnaire for Medication were secondary outcomes. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> RESULTS: Of 322 eligible patients, 250 (77.6%) underwent invasive endotyping; 19 (7.6%) had obstructive coronary disease, 127 (55.0%) had microvascular angina, 27 (11.7%) had vasospastic angina, 17 (7.4%) had both, and 60 (26.0%) had no abnormality. A total of 231 patients (mean age, 55.7 years; 64.5% women) were randomly assigned and followed up (median duration, 19.9 [12.6-26.9] months). The clinician diagnosed vasomotor angina in 51 (44.3%) patients in the intervention group and in 55 (47.4%) patients in the control group. After randomization, patients in the intervention group were 4-fold (odds ratio, 4.05 [95% CI, 2.32-7.24]; <i>P</i> &lt;0.001) more likely to be diagnosed with a coronary vasomotor disorder; the frequency of this diagnosis increased to 76.5%. The frequency of normal coronary function (ie, no vasomotor disorder) was not different between the groups before randomization (51.3% versus 50.9%) but was reduced in the intervention group after randomization (23.5% versus 50.9%, <i>P</i> &lt;0.001). At 6 and 12 months, the Seattle Angina Questionnaire summary score in the intervention versus control groups was 59.2±24.2 (2.3±16.2 change from baseline) versus 60.4±23.9 (4.6±16.4 change) and 63.7±23.5 (4.7±14.7 change) versus 66.0±19.3 (7.9±17.1 change), respectively, and not different between groups (global <i>P</i> =0.36). Compared with the control group, global treatment satisfaction was higher in the intervention group at 12 months (69.9±22.8 versus 61.7±26.9, <i>P</i> =0.013). </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CONCLUSIONS: For patients with angina and no obstructive coronary arteries, a diagnosis informed by invasive functional assessment had no effect on long-term angina burden, whereas treatment satisfaction improved. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> REGISTRATION: URL: https://www. </p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"> CLINICALTRIALS: gov; Unique identifier: NCT03477890.</p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37795617/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37795617</a> | DOI: <a href=https://doi.org/10.1161/CIRCULATIONAHA.123.064751>10.1161/CIRCULATIONAHA.123.064751</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37795617</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Novalia P Sidik</dc:creator><dc:creator> Bethany Stanley</dc:creator><dc:creator> Robert Sykes</dc:creator><dc:creator> Andrew J Morrow</dc:creator><dc:creator> Conor P Bradley</dc:creator><dc:creator> Michael McDermott</dc:creator><dc:creator> Thomas J Ford</dc:creator><dc:creator> Giles Roditi</dc:creator><dc:creator> Allister Hargreaves</dc:creator><dc:creator> David Stobo</dc:creator><dc:creator> Jacqueline Adams</dc:creator><dc:creator> John Byrne</dc:creator><dc:creator> Ahmed Mahrous</dc:creator><dc:creator> Robin Young</dc:creator><dc:creator> David Carrick</dc:creator><dc:creator> Ross McGeoch</dc:creator><dc:creator> David Corcoran</dc:creator><dc:creator> Ninian N Lang</dc:creator><dc:creator> Robert Heggie</dc:creator><dc:creator> Olivia Wu</dc:creator><dc:creator> Margaret B McEntegart</dc:creator><dc:creator> Alex McConnachie</dc:creator><dc:creator> Colin Berry</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> Circulation</dc:source><dc:title> Invasive Endotyping in Patients With Angina and No Obstructive Coronary Artery Disease: A Randomized Controlled Trial</dc:title><dc:identifier> pmid:37795617</dc:identifier><dc:identifier> doi:10.1161/CIRCULATIONAHA.123.064751</dc:identifier></item><item><title> Auditory stimulation of sleep slow waves enhances left ventricular function in humans</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad630. doi: 10.1093/eurheartj/ehad630. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794725/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37794725</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad630>10.1093/eurheartj/ehad630</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794725</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Stephanie Huwiler</dc:creator><dc:creator> Manuel Carro-Domínguez</dc:creator><dc:creator> Fabia M Stich</dc:creator><dc:creator> Rossella Sala</dc:creator><dc:creator> Florent Aziri</dc:creator><dc:creator> Anna Trippel</dc:creator><dc:creator> Tabea Ryf</dc:creator><dc:creator> Susanne Markendorf</dc:creator><dc:creator> David Niederseer</dc:creator><dc:creator> Philipp Bohm</dc:creator><dc:creator> Gloria Stoll</dc:creator><dc:creator> Lily Laubscher</dc:creator><dc:creator> Jeivicaa Thevan</dc:creator><dc:creator> Christina M Spengler</dc:creator><dc:creator> Joanna Gawinecka</dc:creator><dc:creator> Elena Osto</dc:creator><dc:creator> Reto Huber</dc:creator><dc:creator> Nicole Wenderoth</dc:creator><dc:creator> Christian Schmied</dc:creator><dc:creator> Caroline Lustenberger</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Auditory stimulation of sleep slow waves enhances left ventricular function in humans</dc:title><dc:identifier> pmid:37794725</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad630</dc:identifier></item><item><title> Medicine at the dawn of the metaclinical era</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad599. doi: 10.1093/eurheartj/ehad599. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37794638</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad599>10.1093/eurheartj/ehad599</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794638</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Panos E Vardas</dc:creator><dc:creator> Emmanouil P Vardas</dc:creator><dc:creator> Stylianos Tzeis</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> Medicine at the dawn of the metaclinical era</dc:title><dc:identifier> pmid:37794638</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad599</dc:identifier></item><item><title> When technology innovation is the only path to treat patients in economic crisis countries: the Syrian experience</title><link/> https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231009180733&amp;v=2.17.9.post6+86293ac<description> No abstract </description><content:encoded><![CDATA[<div><p style="color: #4aa564;"> Eur Heart J. 2023 Oct 5:ehad634. doi: 10.1093/eurheartj/ehad634. Online ahead of print.</p><p> <b>NO ABSTRACT</b></p><p style="color: lightgray"> PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/37794637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231009180733&v=2.17.9.post6+86293ac">37794637</a> | DOI: <a href=https://doi.org/10.1093/eurheartj/ehad634>10.1093/eurheartj/ehad634</a></p></div> ]]>;</content:encoded><guid ispermalink="false"> pubmed:37794637</guid><pubDate> Thu, 05 Oct 2023 06:00:00 -0400</pubDate><dc:creator> Amr Abdin</dc:creator><dc:creator> Asim Katbeh</dc:creator><dc:creator> Yassin Bani Marjeh</dc:creator><dc:date> 2023-10-05</dc:date><dc:source> European heart journal</dc:source><dc:title> When technology innovation is the only path to treat patients in economic crisis countries: the Syrian experience</dc:title><dc:identifier> pmid:37794637</dc:identifier><dc:identifier> doi:10.1093/eurheartj/ehad634</dc:identifier></item></channel></rss>